This observational, prospective, open-label, multi-center study will evaluate the effectiveness in disease reduction and the safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 11 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01277328?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
